Cizzle Biotechnology Holdings PLC (GB:CIZ)
LSE:CIZ
Want to see GB:CIZ full AI Analyst Report?
CIZ Stock Chart & Stats
1.55 p
<0.01 p(0.26%)
At close: 4:00 PM EST
1.55 p
<0.01 p(0.26%)
Day’s Range― - ―
52-Week Range1.20 p - 3.90 p
Previous CloseN/A
Volume291.66K
Average Volume (3M)1.23M
Market Cap
£12.11M
Enterprise Value12.00M
Total Cash (Recent Filing)£116.00K
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta-0.29
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding424,963,200
10 Day Avg. Volume655,017
30 Day Avg. Volume1,232,506
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-18.07
Price to Sales (P/S)0.00
P/FCF Ratio-12.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Diagnostic Business ModelCizzle's sole focus on blood-based early lung cancer diagnostics concentrates R&D and regulatory strategy on a high-value, clinically needed niche. Successful validation and clinical adoption would create durable demand and a clear commercialization route for a specialized product offering.
Low Reported LeverageMinimal reported debt reduces near-term solvency risk and lowers fixed financing costs, giving management more flexibility in choosing funding routes (equity, grants, partnerships). This conserves runway options while the company pursues clinical validation milestones.
Cash-to-income TransparencyConsistent alignment of free cash flow with net income indicates few large non-cash accounting distortions, improving visibility into true cash burn. That transparency aids planning for financing, milestone timing, and assessment of runway by investors and partners.
Bears Say
Pre-revenue & Persistent LossesThe company reports no revenue and recurring operating losses, meaning business viability depends on future product commercialization. Persisting losses increase capital needs, lengthen time to self-sustainability, and raise execution risk for developing and validating diagnostics.
Eroded Equity And Shrinking AssetsEquity turning negative and a collapsing asset base materially reduce financial flexibility. This impairs borrowing capacity and weakens balance-sheet credibility with partners or regulators, increasing dependence on dilutive financing or restrictive funding terms.
Sustained Negative Operating Cash FlowRepeated negative operating and free cash flows mean ongoing external funding is required to continue R&D and validation programs. Reliance on periodic financing elevates dilution and execution risk, and constrains long-term planning for commercialization investments.
Cizzle Biotechnology Holdings PLC News
CIZ FAQ
What was Cizzle Biotechnology Holdings PLC’s price range in the past 12 months?
Cizzle Biotechnology Holdings PLC lowest share price was 1.20 p and its highest was 3.90 p in the past 12 months.
What is Cizzle Biotechnology Holdings PLC’s market cap?
Cizzle Biotechnology Holdings PLC’s market cap is £12.11M.
When is Cizzle Biotechnology Holdings PLC’s upcoming earnings report date?
Cizzle Biotechnology Holdings PLC’s upcoming earnings report date is Sep 24, 2026 which is in 126 days.
How were Cizzle Biotechnology Holdings PLC’s earnings last quarter?
Cizzle Biotechnology Holdings PLC released its earnings results on Apr 30, 2026. The company reported -0.001 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.001 p.
Is Cizzle Biotechnology Holdings PLC overvalued?
According to Wall Street analysts Cizzle Biotechnology Holdings PLC’s price is currently Overvalued.
Does Cizzle Biotechnology Holdings PLC pay dividends?
Cizzle Biotechnology Holdings PLC does not currently pay dividends.
What is Cizzle Biotechnology Holdings PLC’s EPS estimate?
Cizzle Biotechnology Holdings PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cizzle Biotechnology Holdings PLC have?
Cizzle Biotechnology Holdings PLC has 424,963,200 shares outstanding.
What happened to Cizzle Biotechnology Holdings PLC’s price movement after its last earnings report?
Cizzle Biotechnology Holdings PLC reported an EPS of -0.001 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.636%.
Which hedge fund is a major shareholder of Cizzle Biotechnology Holdings PLC?
Currently, no hedge funds are holding shares in GB:CIZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cizzle Biotechnology Holdings PLC
Cizzle Biotechnology Holdings Plc engages in development of an immunoassay test for the CIZ1B biomarker for the early detection of lung cancer. The company was formerly known as Cizzle Biotechnology Limited and changed its name to Cizzle Biotechnology Holdings Plc in May 2021. Cizzle Biotechnology Holdings Plc is headquartered in London, the United Kingdom.